Descripción del proyecto
Predecir la evolución de la inflamación a la enfermedad
La inflamación crónica es la responsable de muchas enfermedades, ya que provoca lesiones en los órganos de forma silenciosa. La identificación de biomarcadores que puedan ayudar a predecir la inflamación antes de que se manifieste cualquier síntoma, así como a estratificar el riesgo de aparición de enfermedades, constituiría una gran ventaja. Para lograr este objetivo, el equipo del proyecto IMMEDIATE, financiado con fondos europeos, se propone identificar biomarcadores clínicos y ómicos para crear un índice de resiliencia o riesgo de progresión de enfermedad. El trabajo se centrará en el papel de los metabolitos de la microbiota intestinal en la función del sistema inmunitario y la inflamación. Además, los investigadores estudiarán las consecuencias de la modulación de la microbiota intestinal con probióticos sobre la salud y el bienestar. Sus resultados sentarán las bases para un modo de vida más saludable.
Objetivo
IMMEDIATE aims to investigate and explore the diet-microbiome-immunometabolism-axis as a sensor for health-to-disease transition and evaluate strategies to maintain an individual’s well-being. Chronic inflammation is the major root of most diseases. Understanding of this process preceding organ dysfunction or damage and identification of biomarkers in the pre-symptomatic stage and risk but also resilience factors of health-to-disease transition will enable targeted and personalized interventions to prevent irreversible organ damage. Metabolites of gut microbiota are key messengers between diet, microbiota and host, maintaining the balance of pro- and anti-inflammation. Our study takes advantage of cutting-edge omics technologies available within the IMMEDIATE consortium in conjunction with available clinical data and biospecimens from ongoing observational studies, enrolling “healthy” subjects and individuals in the pre-disease stage but with largely distinct environmental and dietary modulators, including a cohort of kidney transplant recipients in whom renal function has been “reset to baseline”. The identification of clinical and omics-derived biomarkers will – by employing AI algorithms - yield a personalized risk / resilience score of chronic inflammation and thus a better prediction of an individual’s risk of transition towards disease. A proof-of-concept intervention study with the anti-inflammatory microbe Akkermansia muciniphila will be conducted to test whether deflections of the microbiome-metabolite-immune axis can be reverted on the biomarker level but also with respect to clinical outcomes and overall well-being. Mobile apps developed by the IMMEDIATE consortium in collaboration with patient organizations tracking numerous lifestyle-related measures and providing guidance and feedback on these aspects will empower individuals to adopt and integrate these knowledge-based health interventions into their own lives, hereby self-managing their own health.
Ámbito científico
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinador
10117 Berlin
Alemania